Halozyme Therapeutics Aktie
55,52
EUR
-0,22
EUR
-0,39
%
65,44
USD
+0,27
USD
+0,41
%
Werbung
Halozyme Therapeutics Aktie Analyse
| 15.11.24 | Halozyme Therapeutics Neutral | JP Morgan Chase & Co. | |
| 11.05.18 | Halozyme Therapeutics Underweight | Barclays Capital | |
| 21.04.17 | Halozyme Therapeutics Market Perform | BMO Capital Markets | |
| 03.11.16 | Halozyme Therapeutics Buy | Deutsche Bank AG | |
| 22.09.15 | Halozyme Therapeutics overweight | Barclays Capital | |
| 03.03.15 | Halozyme Therapeutics Buy | UBS AG | |
| 18.02.15 | Halozyme Therapeutics Buy | MLV Capital | |
| 08.01.15 | Halozyme Therapeutics Buy | MLV Capital | |
|
Werbung
|
|||
| 24.12.14 | Halozyme Therapeutics Buy | MLV Capital | |
| 27.09.12 | Halozyme Therapeutics neutral | UBS AG | |
| 13.06.12 | Halozyme Therapeutics overweight | Barclays Capital | |
| 09.05.12 | Halozyme Therapeutics overweight | Barclays Capital | |
| 09.03.12 | Halozyme Therapeutics overweight | Barclays Capital | |
| 01.04.11 | Halozyme Therapeutics buy | Stifel, Nicolaus & Co., Inc. | |
| 15.03.11 | Halozyme Therapeutics overweight | Barclays Capital | |
| 07.10.10 | Halozyme Therapeutics overweight | Barclays Capital | |
| 13.10.09 | Halozyme Therapeutics outperform | Wedbush Morgan Securities Inc. | |
| 22.04.09 | Halozyme Therapeutics buy | Wedbush Morgan Securities Inc. | |
| 27.02.09 | Halozyme Therapeutics buy | Merriman Curhan Ford & Co | |
| 12.08.08 | Halozyme Therapeutics hold | Brean Murray, Carret & Co., LLC | |
| 22.07.08 | Halozyme Therapeutics | Global Insider Investing | |
| 01.12.06 | Halozyme Therapeutics Buy | Jefferies & Co | |
Werbung
Werbung